Raymond James & Associates Paratek Pharmaceuticals, Inc. Transaction History

Raymond James & Associates

$161 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$4.7 - $7.24 $137,230 - $211,393	-29,198 Closed	0 $0
Q2 2021 Aug 11, 2021	BUY	$6.81 - $10.93 $32,265 - $51,786	4,738 Added 19.37%	29,198 $199,000
Q1 2021 May 14, 2021	SELL	$6.14 - $8.31 $624,732 - $845,525	-101,748 Reduced 80.62%	24,460 $173,000
Q4 2020 Feb 12, 2021	SELL	$4.58 - $7.14 $52,917 - $82,495	-11,554 Reduced 8.39%	126,208 $790,000
Q3 2020 Nov 04, 2020	BUY	$4.19 - $6.69 $426,810 - $681,470	101,864 Added 283.76%	137,762 $745,000
Q2 2020 Jul 28, 2020	SELL	$2.97 - $5.22 $3,118 - $5,481	-1,050 Reduced 2.84%	35,898 $187,000
Q1 2020 Apr 21, 2020	SELL	$2.67 - $4.97 $25,098 - $46,718	-9,400 Reduced 20.28%	36,948 $116,000
Q4 2019 Feb 12, 2020	SELL	$2.93 - $4.5 $35,086 - $53,887	-11,975 Reduced 20.53%	46,348 $187,000
Q3 2019 Nov 07, 2019	SELL	$3.08 - $5.76 $79,464 - $148,608	-25,800 Reduced 30.67%	58,323 $252,000
Q2 2019 Aug 06, 2019	SELL	$3.47 - $6.32 $19,924 - $36,289	-5,742 Reduced 6.39%	84,123 $336,000
Q1 2019 May 06, 2019	SELL	$5.36 - $7.24 $46,433 - $62,720	-8,663 Reduced 8.79%	89,865 $482,000
Q4 2018 Feb 11, 2019	SELL	$4.8 - $11.6 $705 - $1,705	-147 Reduced 0.15%	98,528 $505,000
Q3 2018 Nov 14, 2018	BUY	$9.05 - $10.95 $91,423 - $110,616	10,102 Added 11.41%	98,675 $957,000
Q2 2018 Aug 14, 2018	BUY	$10.2 - $13.9 $805 - $1,098	79 Added 0.09%	88,573 $903,000
Q1 2018 May 14, 2018	BUY	$12.65 - $18.85 $813,863 - $1.21 Million	64,337 Added 266.33%	88,494 $1.15 Million
Q4 2017 Feb 14, 2018	BUY	$17.45 - $25.6 $220,428 - $323,379	12,632 Added 109.61%	24,157 $432,000
Q3 2017 Nov 13, 2017	BUY	$18.9 - $28.2 $217,822 - $325,005	11,525	11,525 $289,000

Others Institutions Holding PRTK

# of Institutions

Shares Held

1.54M

Call Options Held

Put Options Held

View Full List

About Paratek Pharmaceuticals, Inc.

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

More about PRTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account